Burns & complex wounds
Tier-1 and 2 hospitals with active burns and wound units. Predictive grafts where tissue composition, bed readiness, and print params decide outcomes.
Bioprint the exact graft your body needs.
From a wound image to a patient-specific printable graft: tissue composition, bioink, and print parameters computed, not guessed.
Loading NGL…
Collagen · PDB 1BKV · NGL Viewer
Backed by
researchers and early capital.
Partnered with
academia and clinical labs.
The printers are ready. Now give them a brain.
Generic grafts integrate poorly, autografts create donor-site harm, and design stays manual. Cost stays high too: $2.5k to $4k even for simple prints. Zyogen is the image-to-graft stack: deterministic bioink, scaffold, and print params from wet-lab physics, sovereign and on-prem, DPDP & HIPAA ready.
Biology, software, and trust in one stack.
ViT wound maps to interpretable graft signals.
Classify tissue at the patch level, audit what the model sees, then predict whether the bed can take a graft.
Tissue composition
Patch-level ViT map, live classification
24×16
Trust audit
Interpretability on structure-level features
Loading NGL…
Attention on wound biology
Model keys on granulation texture and vascular cues inside the wound bed, a clinically valid signal.
Who it's for.
Hospital-first. India-first. Then global. Hospital SaaS + per-graft fee, priced 30 to 40% below imported equivalents.
Ophthalmology
Corneal and ocular surface programs adopting clinical imaging workflows. Clear SaMD-style routes for prediction software beside the surgeon.
Orthopedics
Cartilage and soft-tissue reconstruction teams already running bioprinters from Cellink, Regemat, 3D Systems, and NBIL in research hospitals.
Research labs
Tissue engineering labs at IITs and AIIMS. India R&D runs 70 to 80% cheaper: build the stack here, then export the method.
SEA & MENA hospitals
Secondary expansion markets where India’s cost advantage compounds. Same hospital SaaS + per-graft model, priced below imported stacks.
US & EU bioprinting centres
Global expansion after proving deployment in India. FDA SaMD and EU MDR routes for clinical prediction software already exist.
Team
product and tissue engineering.
Neha Sarda
Founder & CEO
Built and exited ImpactPlay for cancer patients. Robotics and medtech projects with acquired IP. AI Growth & Insights @ Google (via Canvas8). IEO International Rank 6. 3× valedictorian.
Prof. Falguni Pati
Scientific Collaborator
HOD Biomedical Engineering, IIT Hyderabad. 7,700+ citations, 100+ publications. First author, Nature Communications (2014) on decellularized-ECM bioinks.
Questions & Answers
Learn more about predictive bioprinting with Zyogen.
No. Zyogen automates structure, consistency, and parameter suggestion. Your clinical team leads interpretation and the final graft decision.
No. The stack is deterministic. A physics engine computes bioink formulation, scaffold geometry, and print parameters from wet-lab data, not hallucinated outputs.
A Vision Transformer maps wound tissue composition. Those features feed a predictor grounded in the clinical fact that graft take depends on a clean, vascularized granulation bed.
Medical models can secretly key on rulers, skin tone, or lighting. We audit internals so the system is trusted for the right biological reasons before it informs a decision.
Sovereign deployment: self-hosted and on-prem inside hospital infrastructure, designed for DPDP and HIPAA compliance.
Tier-1 and 2 hospitals with burns, ophthalmology, and orthopedic programs, plus bioprinting research labs at institutions like IITs and AIIMS.
Yes. A hardware translation layer produces toolpaths and extrusion protocols for multi-modal bioprinters already installed in research and clinical settings.